Table 2 Characteristics of included studies in the systematic-review1
First Author, Year (Ref) | Study design | Country | Age range | Gender | Participants (Intervention/control) | Intervention Type | Duration/week | Intervention Dose | Notes about subjects | Study quality | outcome |
|---|---|---|---|---|---|---|---|---|---|---|---|
Aliasgharzadeh et al. [26] | RCT-parallel | Iran | 30–65 | F | 30/25 | resistant dextrin/maltodextrin | 8 | 10 | type 2 diabetes | G | IL-6, TNF-a, CRP |
Peterson et al. [17] | RCT-parallel | United States | 35–75 | M/F | 29/30 | HAM-RS2/Amylopectin | 12 | 45 | prediabetes | F | TNF-a |
Alfa et al. [27] | RCT-parallel | Canada | 30–50 | M/F | 21/21 | MSprebiotic/amioca | 12 | 30 | Healthy subjects | G | TNF-a, CRP |
Karimi et al. [20] | RCT-parallel | Iran | 30–65 | F | 28/28 | Hi-maize 260/ maltodextrin | 8 | 10 | type 2 diabetes | G | CRP |
Tayebi Khosroshahiet al [18]. | RCT-parallel | Iran | ≥18 | M/F | 23/21 | HAM-RS2/waxy starch | 8 | 20 g/d during first 4wk and 25 g/d during second 4 wk | patients on maintenance hemodialysis | G | CRP IL-6, TNF-a |
Meng et al. [28] | parallel, open-label trial | China | 18–80 | M/F | 34/36 | high-RS,low-protein flour | 12 | 17 | Patients With Early Type 2 Diabetic Nephropathy | P | |
Laffin et al. [29] | RCT-parallel | Iran | M/F | 9/11 | HAM-RS2/regular wheat flour | 8 | 20 g/d during first 4wk and 25 g/d during second 4 wk | end-stage renal disease patients | G | IL-6, TNF-a | |
Esgalhado et al. [30] | Pilot RCT-parallel | Brazil | ≥18 | M/F | 15/26 | Hi-maize 260/manioc flour | 4 | 16 | hemodialysis patients | G | IL-6, CRP |
Pourghassem Gargari et al. [31] | RCT-parallel | Iran | 30–65 | F | 28/32 | Hi-maize 260/maltodextrin | 8 | 10 | type 2 diabetes | G | IL-6, TNF-a, CRP |
Lambert-Porcheron et al. [32] | randomized cross-over | France | 20–65 | M/F | 20/20 | high slowly digestible starch/low slowly digestible starch | 6 | 10 | healthy overweight subjects with metabolic risk | P | TNF-a, CRP |
Schioldan et al. [33] | cross-over | Denmark | 39–75 | M/F | 19/19 | 67 g dietary fiber(16 g arabinoxylan+ 21 g RS)/ 18 g dietary fiber (4 g arabinoxylan+ 3 g RS) | 10 | 21 | Metabolic syndrome | P | IL-6 |
Gholizadeh Shamasbi et al. [34] | RCT-parallel | Iran | 18–45 | F | 31/31 | resistant dextrin/ maltodextrin | 12 | 20 | polycystic ovarian syndrome | G | IL-6 |
Penn-Marshall et al. [35] | cross-over | USA | Mean: 36.6 ± 1.55 | M/F | 15/15 | Hi-maize 260/no RS | 8 | 12 | Subjects at risk for type 2 DM. | P | CRP |